| Literature DB >> 32148535 |
Yunqiao Yang1, Lei Guo2, Kinza Tariq1, Weiyu Zhang1, Chong Li1, Fareed Qamar Memon1, Beibei Chai1, Zheng Li1, Junying Sun1, Yunru Chen1, Geyin Zhang1, Qinmei Li1, Shuaiyang Wang1, Lizhen Wang1, Chongbo Lai1, Mingsheng Jiang1, Hongbin Si1.
Abstract
Semiaquilegia adoxoides (DC.) Makino is a herbal medicine and it is recorded that its water extract can be used to treat acute diseases caused by bacterial infections. In order to understand the polysaccharide of Semiaquilegia adoxoides (DC.) Makino (SMP), FT-IR and HPLC methods were performed to determine the basic chemical structure and monosaccharide compositions of SMP. The antioxidant capacity of SMP was analyzed by monitoring both the scavenging rate of DPPH and ABTS free radical. To investigate the effects of SMP on the acute bacterial disease, minimum inhibitory concentrations (MICs) of SMP on E. coli or S. aureus were detected; meanwhile, mice were administrated with SMP for 7 days and then infected with E. coli or S. aureus, and the parameters were measured at the 9th day. Results showed that SMP was a furanose which was mainly composed of glucose (60.3%) and had certain antioxidant activities. Both MIC values of SMP on E. coli and S. aureus were 250 ml/mL, which means that SMP has no direct antibacterial effects. The mice experiments revealed that SMP had potential effects on immunomodulatory by reducing WBC and the expression of serum IL-1, IL-6, and TNF-α and increasing IgM of E. coli or S. aureus infected mice. These findings supported the effect of Semiaquilegia adoxoides (DC.) Makino in folk use with scientific evidence.Entities:
Year: 2020 PMID: 32148535 PMCID: PMC7049844 DOI: 10.1155/2020/2719483
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1DPPH and ABTS radical scavenging activity of SMP. (a) DPPH radicals and (b) ABTS radicals. Note: P < 0.05.
Figure 2FT-IR spectra of SMP.
Figure 3Monosaccharides compositions analysis of STP by HPLC precolumn derivatization. 1: Man, 2: GlcN, 3: Rha, 4: GlcA, 5: GalA, 6: GalN, 7: Glc, 8: Gal, 9: ara, 10: Xyl, and 11: Fuc.
The MIC values of different drugs for E. coli and S. aureus.
|
|
| |
|---|---|---|
| Amikacin ( | 32 | — |
| Vancomycin ( | — | 16 |
| SMP (mg/ml) | 250 | 250 |
Number of survivors and mortality data of each group.
| Group | Control |
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| Total | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
| Deaths | 0 | 13 | 4 | 9 | 14 | 3 | 7 |
| Survivors | 24 | 11 | 20 | 15 | 10 | 22 | 17 |
| Mortality | 0% | 54.2%a | 16.7%b | 37.5%ab | 58.3%A | 12.5%B | 29.2%AB |
Note: line data marked without the same superscripts (a–b or A-B) differ significantly (P < 0.05).
Figure 4The WBC (a) and production of serum IL-1 (b), IL-6 (c), TNF-α (d), and IgM (e) of mice in different groups. Control: uninfected and without intervention. E. coli or S. aureus: infected with E. coli or S. aureus and without intervention. E. coli + amikacin or S. aureus + vancomycin: as positive controls, mice infected with E. coli or S. aureus were subcutaneously injected with amikacin or vancomycin at 5 hours after infection, respectively. E. coli + SMP or S. aureus + SMP: after treated with SMP for 7 days, mice were infected with E. coli or S. aureus. All the bold samples were taken on day 9. Values in a column with different superscripts (a–d, or A-D) were significantly different (P < 0.05).